Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

Autor: Aintzane Sancho Gutiérrez, Alberto Martínez Lorca, Lucía Sanz Gómez, Enrique Grande Pulido, Elena Vida Navas, Teresa Navarro Martínez, Pablo Gajate Borau, Alfredo Carrato Mena
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Adult
Male
Oncology
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
Antineoplastic Agents
Bone Neoplasms
Neutropenia
Neuroendocrine tumors
Octreotide
Lanreotide
lcsh:Diseases of the endocrine glands. Clinical endocrinology
030218 nuclear medicine & medical imaging
03 medical and health sciences
chemistry.chemical_compound
Endocrinology
0302 clinical medicine
Internal medicine
Organometallic Compounds
Sunitinib
medicine
Humans
case report
Everolimus
Progression-free survival
peptide receptor radionuclide therapy
lcsh:RC648-665
neuroendocrine neoplasms
Rectal Neoplasms
business.industry
Pelvic pain
medicine.disease
Magnetic Resonance Imaging
Lu-DOTATATE
chemistry
030220 oncology & carcinogenesis
Retreatment
Radionuclide therapy
Radiopharmaceuticals
neuroendocrine tumors
medicine.symptom
Tomography
X-Ray Computed
business
medicine.drug
Zdroj: Frontiers in Endocrinology, Vol 12 (2021)
Frontiers in Endocrinology
ISSN: 1664-2392
DOI: 10.3389/fendo.2021.676973
Popis: Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-treated with 177Lu-DOTATATE and a literature review about salvage treatment with PRRT. We present a 26-year-old man who started with pelvic pain and after a biopsy of a retro-rectal mass observed in a magnetic resonance was diagnosed with an advanced neuroendocrine tumour. After progression to lanreotide, everolimus and sunitinib, treatment with 177Lu-DOTATATE was initiated, achieving an excellent response with a progression free survival (PFS) of 38 months. At the time of progression, re-treatment with 177Lu-DOTATATE was decided, showing a new partial response, which is currently stable after 15 months. The patient had not presented significant treatment-related toxicity. Although there are no randomized phase III trials or a consensus about the number or dose of cycles, there is evidence about the efficacy and low toxicity of salvage treatment with 177Lu-DOTATATE in NETs. Median progression-free survival ranges from 6 to 22 months. Toxicity is mostly hematologic (anemia and neutropenia), 4-7% grade 3/4.
Databáze: OpenAIRE
Externí odkaz: